Simon N. Pimstone - May 24, 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
CEO, Director
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
May 24, 2021
Transactions value $
-$12,207
Form type
4
Date filed
5/26/2021, 04:11 PM
Next filing
Nov 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $85.1K +22.6K +10.77% $3.76* 233K May 24, 2021 Direct F1
transaction XENE Common Shares Tax liability -$97.3K -5.08K -2.18% $19.17 228K May 24, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -22.6K -100% $0.00* 0 May 24, 2021 Common Shares 22.6K $3.76 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2 Represents the closing price of the Company's common shares on May 21, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
F3 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2011 Vesting Commencement Date.
F4 Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.